We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
Hosted on MSN2d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...
MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback